Efficiency of Monoclonal Antibodies Application against Covid-19

Despite the 20 years history of pathogenic coronavirus infection, methods of prevention and treatment of diseases caused by this infection were not developed yet. One of the reasons could be the features of pathogenesis and a quick spread of the pandemic which may have made researches more complicated. As an inflammatory process develops, a generalization of infection also develops. A cytokine secretion becomes rockets up, Interferon-γ (IFN-y), interleukin-1(IL-1), interleukin-6 (IL-6), interleukin-12 (IL-12), concentration increases. To put it in other words, the primary inflammatory reaction enters a new phase — the cytokine storm phase. In this regard, adequate therapy aimed at stopping the uncontrolled process induced not so much by viremia as by the inflammation associated with it becomes crucial. Therefore, the aim of our research was to study the impact of monoclonal antibodies, in particular the drug "Kazirivimab + Imdevimab" — a combination of recombinant monoclonal antibodies aimed against S-protein on the clinical course and laboratory data in patients with a new coronavirus infection – Covid-19.